Indications for the use of tranylcypromine and trifluoperazine (Parstelin).
Thirty-two patients were treated with the combination of tranylcypromine and trifluoperazine (Parstelin). The patients fell into 3 clinical groups, namely, endogenous depression (7 patients), neurotic depressive reaction (10 patients) and phobic anxiety with some depressive features (15 patients). Satisfactory response was found in 10 out of the 15 patients with phobic symptoms. The response in the other 2 groups was not significant. Side effects were troublesome in the neurotic depressive reaction group. In the phobic group the symptoms of the patients who responded were inclined to recur when the treatment was discontinued. It is considered that it is a useful preparation in the treatment of some phobic patients, but one must expect that the patients are likely to have to remain on the drug for long periods of time.
D000328:Adult; D000368:Aged; D001008:Anxiety Disorders / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy*; D010698:Phobic Disorders / Q000188:drug therapy; D014191:Tranylcypromine / Q000009:adverse effects / Q000627:therapeutic use*; D014268:Trifluoperazine / Q000009:adverse effects / Q000627:therapeutic use*
D014268:Trifluoperazine; D014191:Tranylcypromine